Athens, Greece - March 21, 2019 - RTsafe and Elekta today announced that they have entered into a partnership agreement under which Elekta will provide RTsafe’s innovative 3D printed PseudoPatient™ phantoms combined with 3D remote dosimetry services, to its customers.

RTsafe’s vision is to make Stereotactic Radiosurgery / Radiotherapy (SRS/SRT) more efficient and accessible, with patient-specific quality control procedures that enhance patient safety and empower confidence in using such challenging and advanced radiotherapy techniques. Until recently, the main barrier in place towards that direction was the absence of a truly personalized end-to-end stereotactic QA protocol that verifies the treatment’s overall accuracy, safety and efficiency. RTsafe has developed and patented the PseudoPatient™ Quality Assurance (QA) approach that is capable to overcome this barrier. A unique personalized solution based on real patient anatomy which reproduces and benchmarks the entire clinical SRS/SRT workflow.

RTsafe’s complete armamentarium of solutions (personalized and generic, using 1, 2 and 3D dosimetry services) is currently offered to the whole radiotherapy community by a growing network of distributors, worldwide. In addition, the generic 3D printed PseudoPatient™ phantom combined with 3D remote dosimetry services will be provided also by Elekta via this partnership with RTsafe. Specifically, this agreement ensures that Elekta will be the only linac manufacturer & oncology software developer to offer this service directly to its linac-based SRS/SRT users.
The ultimate common RTsafe and Elekta aim via this collaboration is to increase patient access to cutting-edge SRS/SRT therapies. RTsafe’s technology should make it easier for smaller and non-academic care centers to confidently implement Elekta’s HDRS solution, allowing more patients access to precision radiation medicine.

“RTsafe’s partnership with Elekta – a key and significant global player for the fight against cancer – is a real privilege for our team and will for sure facilitate our company vision towards promoting individualized care in radiation oncology. The honor and responsibility are really high” said Dr. Evangelos Pappas, founder and CEO of RTsafe. “A recently completed consortium study in collaboration with ELEKTA confirmed that the unique combination of Elekta’s Versa HD and RTsafe’s PseudoPatient™ QA approach, inspires confidence in clinical use. Furthermore, we believe that implementing truly patient-specific pre-treatment plan verification for each and every patient is essential for optimizing treatment outcomes. Elekta shares our commitment to advancing radiation therapy as a personalized, precision approach to cancer care. RTsafe could not agree more with Elekta’s moto: ‘Everyone with cancer should have access to – and benefit from – precise, personalized radiotherapy’.”

Rad Oncology Homepage